SEARCH

SEARCH BY CITATION

Progression-free survival in men with advanced prostate cancer is a composite endpoint that has been neither standardized nor validated as a measure of clinical benefit in advanced prostate cancer. The absence of a progression-free survival benefit in this randomized trial of atrasentan leaves the authors uncertain with regard to the potential value of this agent in prostate cancer.